Annals of Hematology

, Volume 92, Issue 6, pp 771–775

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

  • Juan Carlos Hernández-Boluda
  • Arturo Pereira
  • Francisco Cervantes
  • Montse Gómez
  • Eduardo Arellano-Rodrigo
  • Alberto Alvarez-Larrán
  • Francisca Ferrer-Marín
  • Ana Kerguelen
  • José Antonio Márquez
  • María Luisa Antelo
  • Carles Besses
  • on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Original Article

DOI: 10.1007/s00277-013-1683-7

Cite this article as:
Hernández-Boluda, J.C., Pereira, A., Cervantes, F. et al. Ann Hematol (2013) 92: 771. doi:10.1007/s00277-013-1683-7

Abstract

This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.

Keywords

Essential thrombocythemiaTreatmentAnagrelideResponse criteria

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Juan Carlos Hernández-Boluda
    • 1
  • Arturo Pereira
    • 2
  • Francisco Cervantes
    • 3
  • Montse Gómez
    • 1
  • Eduardo Arellano-Rodrigo
    • 2
  • Alberto Alvarez-Larrán
    • 4
  • Francisca Ferrer-Marín
    • 5
  • Ana Kerguelen
    • 6
  • José Antonio Márquez
    • 7
  • María Luisa Antelo
    • 8
  • Carles Besses
    • 4
  • on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
  1. 1.Hematology and Medical Oncology DepartmentHospital Clínico UniversitarioValenciaSpain
  2. 2.Hemotherapy and Hemostasis DepartmentHospital ClínicBarcelonaSpain
  3. 3.Hematology Department, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i SunyerUniversity of BarcelonaBarcelonaSpain
  4. 4.Hematology DepartmentHospital del MarBarcelonaSpain
  5. 5.Hematology and Medical Oncology DepartmentHospital Morales MeseguerMurciaSpain
  6. 6.Hematology DepartmentHospital La PazMadridSpain
  7. 7.Hematology DepartmentHospital BasurtoBilbaoSpain
  8. 8.Hematology DepartmentComplejo Hospitalario de NavarraPamplonaSpain